{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:25:07Z","timestamp":1788996307546,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020480","name":"CSL Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126879","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:39:53Z","timestamp":1739637593000},"page":"126879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs"],"prefix":"10.1016","volume":"51","author":[{"given":"Darvin S.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mould-Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0015","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1038\/s41598-023-30077-1","article-title":"Assessing the impact of one million COVID-19 deaths in America: economic and life expectancy losses","volume":"13","author":"Silva","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126879_bb0030","first-page":"1096","article-title":"Impact of long COVID on productivity and informal caregiving","volume":"25","author":"Kwon","year":"2023","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2025.126879_bb0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.genhosppsych.2024.02.009","article-title":"Prevalence of mental health conditions and brain fog in people with long COVID: a systematic review and meta-analysis","volume":"88","author":"van der Feltz-Cornelis","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126879_bb0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.15585\/mmwr.mm7301a3","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2024","volume":"73","author":"Murthy","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"42","key":"10.1016\/j.vaccine.2025.126879_bb0095","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.15585\/mmwr.mm7242e1","article-title":"Use of updated COVID-19 vaccines 2023-2024 formula for persons aged \u22656 months: recommendations of the advisory committee on immunization practices - United States, September 2023","volume":"72","author":"Regan","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126879_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/jebm.12525","article-title":"Cost-effectiveness of COVID-19 vaccination: a systematic review","volume":"16","author":"Fu","year":"2023","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.vaccine.2025.126879_bb0130","doi-asserted-by":"crossref","first-page":"06001","DOI":"10.7189\/jogh.13.06001","article-title":"Economic evaluation of COVID-19 vaccination: a systematic review","volume":"13","author":"Utami","year":"2023","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13696998.2023.2193067","article-title":"Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4\/BA.5) in the United States","volume":"26","author":"Di Fusco","year":"2023","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13696998.2023.2290388","article-title":"Clinical impact and cost-effectiveness of the updated COVID-19 mRNA autumn 2023 vaccines in Germany","volume":"27","author":"Joshi","year":"2024","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0145","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1080\/13696998.2023.2281083","article-title":"The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States","volume":"26","author":"Kohli","year":"2023","journal-title":"J Med Econ"},{"issue":"15","key":"10.1016\/j.vaccine.2025.126879_bb0150","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.vaccine.2023.01.075","article-title":"mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia","volume":"41","author":"Li","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126879_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2022.03.029","article-title":"Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States","volume":"119","author":"Li","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40258-023-00844-2","article-title":"Cost-effectiveness of the second COVID-19 booster vaccination in the USA","volume":"22","author":"Li","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126879_bb0165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.26502\/jbb.2642-91280116","article-title":"A cost-benefit analysis of bivalent Covid-19 vaccines","volume":"6","author":"Lin","year":"2023","journal-title":"J Biotechnol Biomed"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/vaccines12010074","article-title":"Going forward: potential impact of protein-based COVID-19 vaccination coverage on population outcomes and costs in the United States","volume":"12","author":"Paret","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126879_bb0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.14745\/ccdr.v49i06a03","article-title":"Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: a cost-benefit analysis","volume":"49","author":"Tuite","year":"2023","journal-title":"Can Commun Dis Rep"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2025.126879_bb0180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.14745\/ccdr.v48i78a01","article-title":"Counterfactuals of effects of vaccination and public health measures on COVID-19 cases in Canada: what could have happened?","volume":"48","author":"Ogden","year":"2022","journal-title":"Can Commun Dis Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126879_bb0185","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/vaccines11061089","article-title":"Real-world evidence in cost-effectiveness analysis of enhanced influenza vaccines in adults \u2265 65 years of age: literature review and expert opinion","volume":"11","author":"Postma","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126879_bb0190","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126879_bb0195","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1473-3099(22)00409-1","article-title":"Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant","volume":"22","author":"Higdon","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126879_bb0205","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/vaccines11111711","article-title":"Comparative effectiveness of bivalent (original\/omicron BA.4\/BA.5) COVID-19 vaccines in adults","volume":"11","author":"Kopel","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126879_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126879_bb0215","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/vaccines10122180","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 omicron variant (B.1.1.529): a systematic review with Meta-analysis and Meta-regression","volume":"10","author":"Pratama","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"42","key":"10.1016\/j.vaccine.2025.126879_bb0220","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.15585\/mmwr.mm7142a3","volume":"71","author":"Surie","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1016\/j.vaccine.2025.126879_bb0225","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.15585\/mmwr.mm715152e2","article-title":"Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged \u226565 years - IVY network, 18 states, September 8-November 30, 2022","volume":"71","author":"Surie","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126879_bb0230","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126879_bb0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S2213-2600(22)00354-X","article-title":"Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5152","key":"10.1016\/j.vaccine.2025.126879_bb0240","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.15585\/mmwr.mm715152e1","article-title":"Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION network, nine states, September-November 2022","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0245","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-023-41537-7","article-title":"mRNA-1273 bivalent (original and omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126879_bb0250","doi-asserted-by":"crossref","first-page":"05022","DOI":"10.7189\/jogh.12.05022","article-title":"Cost-effectiveness of interventions for the prevention and control of COVID-19: systematic review of 85 modelling studies","volume":"12","author":"Zhou","year":"2022","journal-title":"J Glob Health"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126879_bb0260","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/vaccines11020234","article-title":"The societal value of vaccines: expert-based conceptual framework and methods using COVID-19 vaccines as a case study","volume":"11","author":"Di Fusco","year":"2023","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126879_bb0275","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/heartjnl-2023-323483","article-title":"The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications","volume":"110","author":"Mercade-Besora","year":"2024","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126879_bb0280","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S2215-0366(22)00260-7","article-title":"Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients","volume":"9","author":"Taquet","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"31","key":"10.1016\/j.vaccine.2025.126879_bb0285","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15585\/mmwr.mm7131a3","article-title":"Post-COVID-19 symptoms and conditions among children and adolescents - United States, march 1, 2020-January 31, 2022","volume":"71","author":"Kompaniyets","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126879_bb0290","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","article-title":"Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales","volume":"146","author":"Knight","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2025.126879_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101783","article-title":"Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study","volume":"56","author":"Chang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"30","key":"10.1016\/j.vaccine.2025.126879_bb0300","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1016\/j.vaccine.2022.04.026","article-title":"Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts","volume":"40","author":"Postma","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126879_bb0305","article-title":"The Socioeconomic Value of Adult Immunisation Programmes","author":"El Banhawi","year":"2024"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126879_bb0310","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1186\/s12889-022-14148-y","article-title":"Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19","volume":"22","author":"Patenaude","year":"2022","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126879_bb0315","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/vaccines10081320","article-title":"Estimates of the global burden of COVID-19 and the value of broad and equitable access to COVID-19 vaccines","volume":"10","author":"Bell","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126879_bb0320","author":"Knight","year":"2025"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126879_bb0330","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126879_bb0335","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S1473-3099(24)00615-7","article-title":"12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2025.126879_bb0340","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against omicron subvariants","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:40:51Z","timestamp":1762278051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"alternative-id":["S0264410X25001768"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126879","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126879"}}